期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

近年来帕金森病药物临床试验的启示 被引量：3

原文传递
导出
摘要 帕金森病（PD）是中老年常见的神经变性疾病，病因和发病机制迄今未明，疾病控制仍以药物对症治疗为主。然而何时进行药物治疗更有利于患者，目前仍有争议。多数的观念认为，在早期症状不影响患者生活和工作时，可以推迟对症治疗以延缓运动并发症的发生。
作者 陈海波 苏闻
机构地区 卫生部北京医院神经内科
出处 《中华神经科杂志》 CAS CSCD 北大核心 2011年第12期801-804,共4页 Chinese Journal of Neurology
关键词 药物临床试验 帕金森病 神经变性疾病 对症治疗 运动并发症 发病机制 疾病控制 药物治疗
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献24

  • 1Clarke CE,Pate Sl,Ives N,et al.Should treatment for Parkinson ' s disease start immediately on diagnosis or delayed until functional disability develops? Mov Disord,2011,26:1187-1193.
  • 2Olanow CW,Watts RL,Koller WC.An algorithm (decision tree)for the management of Parkinson' s disease (2001):treatment guidelines.Neurology,2001,56 (11 Suppl 5):S1-88.
  • 3P(a)lhagen S,Heinonen E,H(a)gglund J,et al.Selegiline slows the progression of the symptoms of Parkinson disease.Neurology,2006,66:1200-1206.
  • 4Parkinson Study Group.A controlled trial of rasagiline in early Parkinson disease-the TEMPO study.Arch Neurol,2002,59:1937-1943.
  • 5Hauser RA,Lew MF,Hurtig HI,et al.Long-term outcome of early versus delayed rasagiline treatment in early Parkinson' s disease.Mov Disord,2009,24:564-573.
  • 6Parkinson Study Group CALM Cohort Investigators.Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.Arch Neurol,2009,66:563-570.
  • 7Lees AJ.Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early,mild Parkinson' s disease.Parkinson' s disease research group of the United Kindom.BMJ,1995,311:1602-1607.
  • 8Olanow CW,Myllyla VV,Sotaniemi KA,et al.Effect of selegiline on mortality in patients with Parkinson' s disease:a meta-analysis.Neurology,1998,51:825-830.
  • 9Mizuno Y,Kondo TT,Kuno S,et al.Early addition of selegiline to L-dopa treatment is beneficial for patients with Parkinson disease.Clin Neuropharm,2010,33:1-4.
  • 10Rascol O,Fitzer-Attas CJ,Hauser R,et al.A double-blind,delayed-start trial of rasagiline in Parkinson' s disease (the ADAGIO study):prespecified and post-hoc analyses of the need for additional therapies,changes in UPDRS scores,and non-motor outcomes.Lancet Neurol,2011,10:415-423.

二级参考文献27

  • 1陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量：103
  • 2温洪波,张振馨,罗毅,陈生弟,蒋雨平,张小英,孙相如,王新德,姚晨.普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J].中华神经科杂志,2006,39(9):604-608. 被引量：63
  • 3Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson' s disease. N Engl J Med, 1993, 328 : 176-183.
  • 4Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson' s disease. Mov Disord, 2008, 24:562-571.
  • 5Bonuccelli U, Pavese N. Role of dopamine agonists in Parkinson' s disease : an update. Expert Rev Neurother, 2007, 7 : 1391-1399.
  • 6Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol, 2002, 59 : 1541-1550.
  • 7Albin RL, Frey KA. Initial agonist treatment of Parkinson disease : a critique. Neurology, 2003, 60 : 390-394.
  • 8Olanow W, Schapira AH, Rascol O. Continuous dopamine- receptor stimulation in early Parkinson' s disease. Trends Neurosci, 2000, 23 ( 10 Suppl) : Sl17-126.
  • 9Olanow CW, Watts RL, Koller WC. An algorithm ( decision tree) for the management of Parkinson' s disease ( 2001 ) : treatment guidelines. Neurology, 2001,56 ( 11 Suppl 5 ) : S1-S88.
  • 10Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson' s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I : early (uncomplicated) Parkinson' s disease. Eur J Neurol, 2006, 13 : 1170-1185.

共引文献173

同被引文献71

  • 1马顺天.帕金森病误诊28例分析[J].中华全科医师杂志,2005,4(8):500-501. 被引量：3
  • 2张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量：619
  • 3中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第二版)[J].中华神经科杂志,2009,42:352-355.
  • 4Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update [J]. Am Fam Physician, 2013, 87: 267-273.
  • 5Kaplan S, Tarsy D. Initial treatment of Parkinson' s disease: an update [ J]. Curr Treat Options Neurol, 2013, 15:377-384.
  • 6Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson' s disease-related pathology [ J ]. Cell Tissue Res, 2004, 318: 121-134.
  • 7Grosset DG, Schapira AH. Timing the initiation of treatment in Parkinson' s disease [ J]. J Neurol Neurosurg Psychiatry, 2008, 79: 615.
  • 8Mcghee D J, Royle PL, Thompson PA, et al. A systematic review of biomarkers for disease progression in Parkinson' s disease [ J]. BMC Neurol, 2013, 13 : 35.
  • 9Brack A, Aalto S, Rauhala E, et al. A follow-up study on 6- [ 18F] fluoro-L-dopa uptake in early Parkinson' s disease shows nonlinear progression in the putameu [ J ]. Mov Disord, 2009, 24: 1009-1015.
  • 10Lipski J, Nistico R, Berretta N, et al. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson' s disease? [ J]. Prog Neumbiol, 2011,94: 389-407.

引证文献3

二级引证文献21

中华神经科杂志
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部